Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3456 | 0.4427 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.0588 | 0.5 |
Schistosoma mansoni | methyl-cpg binding protein mbd | 0.0021 | 0.0294 | 0.0366 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.0588 | 0.0411 |
Schistosoma mansoni | zinc finger protein | 0.0024 | 0.0717 | 0.0891 |
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.0894 | 0.1112 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.0588 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3456 | 0.4427 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.0588 | 0.0411 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0588 | 0.0731 |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0021 | 0.0294 | 0.0366 |
Brugia malayi | PHD-finger family protein | 0.003 | 0.161 | 0.1086 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0588 | 0.0731 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0023 | 0.0588 | 1 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.7437 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0588 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.7437 | 1 |
Echinococcus multilocularis | zinc finger protein | 0.0024 | 0.0717 | 0.0592 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.4261 | 0.4413 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.3864 | 0.3972 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.9283 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.0588 | 1 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.0588 | 0.0327 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0027 | 0.1214 | 0.1287 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.0588 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0023 | 0.0588 | 1 |
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.8037 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0023 | 0.0588 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0.0588 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.0588 | 0.5 |
Schistosoma mansoni | methyl-cpg binding protein mbd | 0.0021 | 0.0294 | 0.0366 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.3853 | 0.3469 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0027 | 0.1214 | 0.1287 |
Schistosoma mansoni | histone-lysine n-methyltransferase setb1 | 0.0021 | 0.0294 | 0.0366 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0023 | 0.0588 | 0.5 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0027 | 0.1214 | 0.151 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0025 | 0.0894 | 0.0667 |
Toxoplasma gondii | exonuclease III APE | 0.0023 | 0.0588 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.0588 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0588 | 0.5 |
Loa Loa (eye worm) | bromodomain containing protein | 0.0021 | 0.0397 | 0.0114 |
Echinococcus granulosus | zinc finger protein | 0.0024 | 0.0717 | 0.0592 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.4581 | 0.4769 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0.0588 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0398 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.7079 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 4.1475 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 8.9125 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 14.1254 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 112.2018 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.